Triclabendazole

Triclabendazole

File:Triclabendazole.png
Systematic (IUPAC) name
5-chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole
Clinical data
Pregnancy category	?
Routes of administration	?
Legal status
Legal status	?
Pharmacokinetic data
Metabolism	oxidation to the sulfone and sulfoxide parent compound
Biological half-life	22 - 24 hs
Excretion	>95% in faeces, 2% in urine, and < 1% in milk
Identifiers
CAS Number	68786-66-3
ATC code	P02BX04 (WHO) QP52AC01
PubChem	CID 50248
Chemical data
Formula	C14H9Cl3N2OS
Molar mass	359.658[[]]

Triclabendazole (commercial names: veterinary, liquid: Fasinex; human, tablets: Egaten; both manufactured by Novartis) is a member of the benzimidazole family of anthelmintics. The benzimidazole drugs share a common molecular structure, triclabendazole being the exception in having a chlorinated benzene ring but no carbamate group.

Triclabendazole was initially only developed as an oral route drug and displays high efficacy against both immature and adult liver fluke.

It is generally accepted that benzimidazoles like triclabendazole bind to beta-tubulin and prevent the polymerisation of the microtubules of which they are part.

Since latter nineties, triclabendazole came into generic situation as patents expired in many countries. Many products were developed then. Among them, Trivantel 15, a 15% triclabendazole suspension was launched by Agrovet Market Animal Health in early 2000s. In 2009, the first triclabendazole injectable solution (combined with ivermectin) was developed and launched also by Agrovet Market Animal Health. The product, Fasiject Plus, a triclabendazole 36% and ivermectin 0.6% solution, is designed to treat Fasciola hepatica (both immature and adult liver fluke), roundworms and ectoparasites as well.

External links

• Fasiject Plus (a brand of triclabendazole + ivermectin) Website
• Agrovet Market Animal Health Multilanguage Website

cs:Triklabendazol